NDC 70661-005

LYPQOZET

(ezetimibe And Atorvastatin)

LYPQOZET is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Althera Pharmaceuticals, Llc. The primary component is Atorvastatin Calcium Trihydrate; Ezetimibe.

Product ID70661-005_bd0e8df1-2810-4543-8600-ad6c45c399d6
NDC70661-005
Product TypeHuman Prescription Drug
Proprietary NameLYPQOZET
Generic Name(ezetimibe And Atorvastatin)
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2021-01-14
Marketing CategoryANDA /
Application NumberANDA206084
Labeler NameAlthera Pharmaceuticals, LLC
Substance NameATORVASTATIN CALCIUM TRIHYDRATE; EZETIMIBE
Active Ingredient Strength10 mg/1; mg/1
Pharm ClassesDecreased Cholesterol Absorption [PE], Dietary Cholesterol Absorption Inhibitor [EPC], HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70661-005-30

30 TABLET in 1 BOTTLE (70661-005-30)
Marketing Start Date2021-01-14
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "LYPQOZET" or generic name "(ezetimibe And Atorvastatin)"

NDCBrand NameGeneric Name
70661-005LYPQOZET(ezetimibe and atorvastatin)
70661-006LYPQOZET(ezetimibe and atorvastatin)
70661-007LYPQOZET(ezetimibe and atorvastatin)
70661-008LYPQOZET(ezetimibe and atorvastatin)

Trademark Results [LYPQOZET]

Mark Image

Registration | Serial
Company
Trademark
Application Date
LYPQOZET
LYPQOZET
98556848 not registered Live/Pending
Norvium Bioscience LLC
2024-05-17
LYPQOZET
LYPQOZET
90200157 not registered Live/Pending
Althera Pharmaceuticals LLC
2020-09-22

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.